1MOORE J D,DEZUBE B J,GILL P,et al.Phase I dose escalation pharmacokinetics of O(chloroecetylcarbamoyl)fumagillol(TNP-470)and its metabolites in AIDS patients with Kappsi's sarcoma[J].Cancer Chemother Pharmacol,2000,46(3):173-179.
2KUDELKA A P,LEVY T,VERSCHRAEGEN C F,et al.A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix[J].Clin Cancer Res,1997,3(9):1501-1505.
3THOMAS J P,ARZOOMANIAN R Z,ALBERTID,et al.Phase I pharmacokinetics and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors[J].J Clin Oncol,2003,21(2):223-231.
4STEW ARD W P,THOMAS A L.Marimastat:the clinical development of a matrix metalloproteinase inhibitor[J].Expert Opin Investig Drugs,2000,9(12):2913-2922.
5SCATENA R.Prinomastat,a hydroxanate-based of matrix metalloproteinases inhibitor,A novel pharmacological approach for tissue remodeling-related diseases[J].Expert Opin Investig Drugs,2000,9(9):2159-2165.
6POSEY J A, KHAZAELI M B, DEL GROSSO A, et al. A pilot trial of Vitaxin,a humanized anti- vitronectin receptor (anti alpha beta3) antibody in patients with metastatic cancer [J ]. Cancer Biother Radiopharm,2001,16(2) : 125 - 132.
7GORDON M S,MARGOLIN K,TALPAZ M,et al. Phase I safety and pharmacokinetic trial of recombinant human monoclonal anti - vascular endothelial growth factor in patients with advanced cancer[J] .J Clin Oncol,2001,19(3) :843 - 850.
8STOPECK A, SHELDON M, VAHECLIAN M, et al. Results of a phase I dose - escalating study of the antiangingenic agent (SU 5416) in patients with advanced malignancies[J ]. Clin Cancer Res,2002,8(9) :2 798 - 2 805.
9LAIRD A D, VAJKOCZY P, SHAWVER L K, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors [ J ]. Cancer Res, 2000, 60 ( 15 ) : 4 152 -4 160.
10LEIBOWITZ R, TUCKER S J. PSA response to thalidomide in patients with advanced prostate cancer[J]. Oncology, 2002, 16(9):1 146- 1 148.
